309 related articles for article (PubMed ID: 30665945)
21. Selective targeting of PARP-2 inhibits androgen receptor signaling and prostate cancer growth through disruption of FOXA1 function.
Gui B; Gui F; Takai T; Feng C; Bai X; Fazli L; Dong X; Liu S; Zhang X; Zhang W; Kibel AS; Jia L
Proc Natl Acad Sci U S A; 2019 Jul; 116(29):14573-14582. PubMed ID: 31266892
[TBL] [Abstract][Full Text] [Related]
22. Hyper-active non-homologous end joining selects for synthetic lethality resistant and pathological Fanconi anemia hematopoietic stem and progenitor cells.
Du W; Amarachintha S; Wilson AF; Pang Q
Sci Rep; 2016 Feb; 6():22167. PubMed ID: 26916217
[TBL] [Abstract][Full Text] [Related]
23. Differential requirement for H2AX and 53BP1 in organismal development and genome maintenance in the absence of poly(ADP)ribosyl polymerase 1.
Orsburn B; Escudero B; Prakash M; Gesheva S; Liu G; Huso DL; Franco S
Mol Cell Biol; 2010 May; 30(10):2341-52. PubMed ID: 20231360
[TBL] [Abstract][Full Text] [Related]
24. Polymerase independent repression of FoxO1 transcription by sequence-specific PARP1 binding to FoxO1 promoter.
Tian YN; Chen HD; Tian CQ; Wang YQ; Miao ZH
Cell Death Dis; 2020 Jan; 11(1):71. PubMed ID: 31992690
[TBL] [Abstract][Full Text] [Related]
25. MORC2 regulates DNA damage response through a PARP1-dependent pathway.
Zhang L; Li DQ
Nucleic Acids Res; 2019 Sep; 47(16):8502-8520. PubMed ID: 31616951
[TBL] [Abstract][Full Text] [Related]
26. The phytochemical 3,3'-diindolylmethane decreases expression of AR-controlled DNA damage repair genes through repressive chromatin modifications and is associated with DNA damage in prostate cancer cells.
Palomera-Sanchez Z; Watson GW; Wong CP; Beaver LM; Williams DE; Dashwood RH; Ho E
J Nutr Biochem; 2017 Sep; 47():113-119. PubMed ID: 28582660
[TBL] [Abstract][Full Text] [Related]
27. Restoration of KMT2C/MLL3 in human colorectal cancer cells reinforces genome-wide H3K4me1 profiles and influences cell growth and gene expression.
Larsson C; Cordeddu L; Siggens L; Pandzic T; Kundu S; He L; Ali MA; Pristovšek N; Hartman K; Ekwall K; Sjöblom T
Clin Epigenetics; 2020 May; 12(1):74. PubMed ID: 32471474
[TBL] [Abstract][Full Text] [Related]
28. Enhanced non-homologous end joining contributes toward synthetic lethality of pathological RAD51C mutants with poly (ADP-ribose) polymerase.
Somyajit K; Mishra A; Jameei A; Nagaraju G
Carcinogenesis; 2015 Jan; 36(1):13-24. PubMed ID: 25292178
[TBL] [Abstract][Full Text] [Related]
29. Poly(ADP-ribosyl)ation of BRD7 by PARP1 confers resistance to DNA-damaging chemotherapeutic agents.
Hu K; Wu W; Li Y; Lin L; Chen D; Yan H; Xiao X; Chen H; Chen Z; Zhang Y; Xu S; Guo Y; Koeffler HP; Song E; Yin D
EMBO Rep; 2019 May; 20(5):. PubMed ID: 30940648
[TBL] [Abstract][Full Text] [Related]
30. [Molecular mechanisms of regulaion of transcription by PARP1].
Maliuchenko NV; Kulaeva OI; Kotova E; Chupyrkina AA; Nikitin DV; Kirpichnikov MP; Studitskiĭ VM
Mol Biol (Mosk); 2015; 49(1):99-113. PubMed ID: 25916114
[TBL] [Abstract][Full Text] [Related]
31. c-MYC suppresses BIN1 to release poly(ADP-ribose) polymerase 1: a mechanism by which cancer cells acquire cisplatin resistance.
Pyndiah S; Tanida S; Ahmed KM; Cassimere EK; Choe C; Sakamuro D
Sci Signal; 2011 Mar; 4(166):ra19. PubMed ID: 21447800
[TBL] [Abstract][Full Text] [Related]
32. Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors.
Hopkins TA; Shi Y; Rodriguez LE; Solomon LR; Donawho CK; DiGiammarino EL; Panchal SC; Wilsbacher JL; Gao W; Olson AM; Stolarik DF; Osterling DJ; Johnson EF; Maag D
Mol Cancer Res; 2015 Nov; 13(11):1465-77. PubMed ID: 26217019
[TBL] [Abstract][Full Text] [Related]
33. PARP1 inhibitor olaparib (Lynparza) exerts synthetic lethal effect against ligase 4-deficient melanomas.
Czyż M; Toma M; Gajos-Michniewicz A; Majchrzak K; Hoser G; Szemraj J; Nieborowska-Skorska M; Cheng P; Gritsyuk D; Levesque M; Dummer R; Sliwinski T; Skorski T
Oncotarget; 2016 Nov; 7(46):75551-75560. PubMed ID: 27705909
[TBL] [Abstract][Full Text] [Related]
34. LMO2 Confers Synthetic Lethality to PARP Inhibition in DLBCL.
Parvin S; Ramirez-Labrada A; Aumann S; Lu X; Weich N; Santiago G; Cortizas EM; Sharabi E; Zhang Y; Sanchez-Garcia I; Gentles AJ; Roberts E; Bilbao-Cortes D; Vega F; Chapman JR; Verdun RE; Lossos IS
Cancer Cell; 2019 Sep; 36(3):237-249.e6. PubMed ID: 31447348
[TBL] [Abstract][Full Text] [Related]
35. New perspectives on the plant PARP family: Arabidopsis PARP3 is inactive, and PARP1 exhibits predominant poly (ADP-ribose) polymerase activity in response to DNA damage.
Gu Z; Pan W; Chen W; Lian Q; Wu Q; Lv Z; Cheng X; Ge X
BMC Plant Biol; 2019 Aug; 19(1):364. PubMed ID: 31426748
[TBL] [Abstract][Full Text] [Related]
36. PARP1 Links CHD2-Mediated Chromatin Expansion and H3.3 Deposition to DNA Repair by Non-homologous End-Joining.
Luijsterburg MS; de Krijger I; Wiegant WW; Shah RG; Smeenk G; de Groot AJL; Pines A; Vertegaal ACO; Jacobs JJL; Shah GM; van Attikum H
Mol Cell; 2016 Feb; 61(4):547-562. PubMed ID: 26895424
[TBL] [Abstract][Full Text] [Related]
37. Poly(ADP‑ribose) polymerase 1/2 inhibitors decrease the ubiquitination of ALC1 mediated by CHFR in breast cancer.
Wang Y; Wang Y; Wang N; You L; Long F; Shao C; Wang Y; Wu J
Oncol Rep; 2019 Oct; 42(4):1467-1474. PubMed ID: 31322269
[TBL] [Abstract][Full Text] [Related]
38. Down-regulation of poly (ADP-ribose) polymerase 1 leads to change of hydroquinone cytotoxicity in TK6 cells.
Sha Y; Zhou W; Yang Z; Zhu X; Yang X; Li TD; Zhu D
Toxicol Mech Methods; 2015; 25(6):467-77. PubMed ID: 26335980
[TBL] [Abstract][Full Text] [Related]
39. Targeting the DNA Damage Response for Cancer Therapy.
Wang R; Sun Y; Li C; Xue Y; Ba X
Int J Mol Sci; 2023 Nov; 24(21):. PubMed ID: 37958890
[TBL] [Abstract][Full Text] [Related]
40. A Cyclin-Dependent Kinase Inhibitor, Dinaciclib, Impairs Homologous Recombination and Sensitizes Multiple Myeloma Cells to PARP Inhibition.
Alagpulinsa DA; Ayyadevara S; Yaccoby S; Shmookler Reis RJ
Mol Cancer Ther; 2016 Feb; 15(2):241-50. PubMed ID: 26719576
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]